ClinicalTrials.gov record
Completed Phase 2 Interventional

Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma

ClinicalTrials.gov ID: NCT00002634

Public ClinicalTrials.gov record NCT00002634. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 12:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

N7: EVALUATION OF MAXIMAL CHEMOTHERAPY DOSE INTENSITY PLUS MONOCLONAL ANTIBODY 3F8 IN THE TREATMENT OF NEUROBLASTOMA

Study identification

NCT ID
NCT00002634
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Enrollment
45 participants

Conditions and interventions

Conditions

Interventions

  • autologous bone marrow transplantation Procedure
  • cisplatin Drug
  • cyclophosphamide Drug
  • doxorubicin hydrochloride Drug
  • etoposide Drug
  • filgrastim Biological
  • in vitro-treated bone marrow transplantation Procedure
  • low-LET cobalt-60 gamma ray therapy Radiation
  • low-LET photon therapy Radiation
  • mesna Drug
  • monoclonal antibody 3F8 Biological
  • perfosfamide Drug
  • radioisotope therapy Radiation
  • vincristine sulfate Drug

Procedure · Drug · Biological + 1 more

Eligibility (public fields only)

Age range
1 Year and older
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 1995
Primary completion
Aug 31, 2004
Completion
Aug 31, 2004
Last update posted
Jul 2, 2013

1995 – 2004

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Memorial Sloan-Kettering Cancer Center New York New York 10021

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00002634, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 2, 2013 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00002634 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →